ARCHIVES

Addition of Cobimetinib Boosts PFS in BRAF Mutation-Positive Patients in Phase III Trial

This article is from The Cancer Letter archive.

Vol. 37 No. 7 | July 25, 2014

Download PDF Visit The Full Archive

Related Articles

Five Years after Proton Therapy, 75-99% of Men Live Cancer-Free

February 28, 2014

NIH Cool On OIG, But the Awardees Love it, DeVita Says

October 17, 1986

In Brief: FASEB Report On Diet and Cancer Mortality Available; Don Poppke AO of Nursing Center

March 6, 1987

Clinical Trials System “Slowly Unraveling,”

March 7, 2008

Oncologists Tell Congress Community Cancer Practices Are Not Adequately Reimbursed

April 4, 2014

Pepper Committee, Impressed By Progress Reports, Promises Help With NCI Funding

June 29, 1979